Nektar Therapeutics (NKTR)
Nektar Therapeutics at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.
Nektar Therapeutics (NKTR) is a Biotechnology company based in US with a market capitalization of $1.3B. Revenue declined 43.9% year-over-year and free cash flow was negative at -$208.7M. This page tracks NKTR's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.
US · 61 employees · IPO May 3, 1994
Valuation
Valuation & price
$70.62as of May 17, 2026· -29.6% vs 52w high
—
P/E ratio
Latest-FY diluted EPS
14.03
P/B ratio
Market cap ÷ book equity
—
Dividend yield
Price — last 12 months
Fundamentals
Key fundamentals
$1.3B
Market cap
-43.9%
Revenue growth (YoY)
100.0%
Gross margin
-$208.7M
Free cash flow (USD)
-$96.8M
Net debt
Net cash position
23.1%
Share dilution
0/5
Graham criteria passed
Defensive-investor screen
Healthcare
Sector
Trajectory
Long-term trends
Revenue by year
2016 → 2025
Free cash flow by year
2016 → 2025
Gross margin by year
2021 → 2025
Value screen
Graham defensive-investor tests
0
Insider buys · 90 days
5
Insider sells · 90 days
Earnings
Last report: 10-Q filed May 8, 2026
Next expected: not yet scheduled
On the tape
Recent SEC & insider activity
- Insider sellJul 2, 2026Filing
Insider Sell $398K · 10b5-1 PlanZalevsky Jonathan · Chief R&D Officer · $397.7K
- Insider sellJun 18, 2026Filing
Insider Sell $1.2M · 10b5-1 PlanROBIN HOWARD W · Director, President & CEO · $1.2M
- Insider sellJun 17, 2026Filing
Insider Sell $336K · 10b5-1 PlanZalevsky Jonathan · Chief R&D Officer · $336.2K
- 8-K eventJun 5, 2026Filing
Annual Meeting Results
- Insider sellMay 21, 2026Filing
Insider Sell $29KROBIN HOWARD W · Director, President & CEO · $29.1K
- Insider sellMay 21, 2026Filing
Insider Sell $13KZalevsky Jonathan · Chief R&D Officer · $13K
- Quarterly reportMay 8, 2026Filing
10-Q Filed
- 8-K eventMay 8, 2026Filing
Equity Distribution Agreement
- 8-K eventMay 7, 2026Filing
Earnings Release
- 8-K eventApr 23, 2026Filing
Common Stock Offering
Questions
Frequently asked questions
What is Nektar Therapeutics's market cap?
Nektar Therapeutics (NKTR) has a market capitalization of $1.3B.
What is NKTR's P/E ratio?
A meaningful P/E ratio is not available for NKTR — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.
What is NKTR's price-to-book (P/B) ratio?
NKTR trades at 14.03 times book value per share.
Are insiders buying NKTR stock?
SEC Form 4 filings show no open-market insider buys at Nektar Therapeutics in the last 90 days (5 sells).
Same arena
Related companies in Biotechnology
Timeline
Every filing, insider trade & earnings on a price-anchored timeline
Filing Analyzer
Search the actual 10-K / 10-Q text with AI research angles
News
Latest press coverage in one feed
Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.